ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
FAIL · Does not pass the screen
15.73 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 12:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price15.73 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 2.96)
Last reviewed28 Oct 2026 (2 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 15.73 against the desk's fair-value range, base estimate 31.46, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.96, read 2026-10-29
Ethical does not pass the values gate
Price15.73 USD
Fair value31.46
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Distribution15.09+4.2% to today Markdown gives way to Distribution after a 49% slide in 9 days
2026-10-02Read Markdown29.74-47.1% to today ✓Accumulation gives way to Markdown after a 5% slide in 6 weeks
2026-08-22Read Accumulation31.46-50.0% to today Markdown gives way to Accumulation
2026-07-02Read Markdown30.54-48.5% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ArriVent BioPharma, Inc. holds its Distribution at $15.73. Consolidating, no directional conviction, held for 10 days.
As held on the ledger · 2026-10-28
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 10 days
Price at the screen
$15.73
Valuation
N/A trailing · -3.84 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.35
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
80.22%
Below 33%
Interest-bearing cash and securities are 80.2% of assets, above the one-third limit.
Fail
Receivables
13.69%
Below 49%
Money owed to the company is 13.7% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
ArriVent BioPharma,'s business is fine, but its cash and interest-bearing securities are about 80% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVBP's ethical verdict changes
Today AVBP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +186% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage cancer bets with missing numbers
Picture a lab racing to turn one promising molecule into a cancer drug that patients actually need. ArriVent is exactly that story, yet it posts zero profit, negative returns on equity and a forward multiple that signals losses ahead. With no financial ratios available the ethical screen simply cannot clear it.
We therefore pass. Analyst targets sit above the current price and the lead candidate looks interesting on paper, but the absence of usable data leaves us unable to judge governance or long term sustainability.
Risks sit in the usual biotech traps of trial failure, dilution and cash burn that never turns into revenue. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVBP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Distribution$16.79+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-10-18Distribution$16.79+11.3%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 11.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 49.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-10-02Markdown · changed$29.74+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-09-24Accumulation$29.74-5.5%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-22Markdown$33.19+8.7%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-18Markdown$30.54+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-03Markdown$30.54+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$30.54Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
